Changing to Avastin could save NHS £100m a year - Cameron Optometry | Cameron Optometry
Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

The value of having independent prescribing optometrists

16th September 2020

Some patients might be interested in this article where Ian Cameron shares his thoughts on prescribing. We were one of the first practices to have an optometrist who could prescribe medication to pati...

Read more

Back to school eye examinations

11th August 2020

We are normally inundated with children visiting the practice during the summer months, with parents and carers booking in an eye examination, along with a fitting for school shoes, stationery orders,...

Read more

Coronavirus, COVID-19, advice

03rd August 2020

This page will have our latest information on the care we can provide during the COVID-19 pandemic. You can also find information on our Facebook page. LATEST UPDATE 1.30pm, Monday, 3 August: Resu...

Read more

How to avoid digital eyestrain when working from home

26th May 2020

Last week we provided advice on how to prevent your child suffering from digital eyestrain. This week, we're looking at adults, in particular those working from home (most of us at the moment!). Ian...

Read more